Cover
Cover | Apr. 20, 2024 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | This Amendment No. 1 to Current Report on Form 8-K (the “Form 8-K/A”) amends and restates the Current Report on Form 8-K of ArriVent BioPharma, Inc. (the “Company”) filed with the U.S. Securities and Exchange Commission on April 22, 2024 (the “Original Form 8-K”), which reported the appointment of Kristine Peterson to the Company’s Board of Directors. This Form 8-K/A is being filed to amend and restate Item 5.02 of the Original Form 8-K to provide, among other things, the committee assignment information omitted from the Original Form 8-K. |
Document Period End Date | Apr. 20, 2024 |
Entity File Number | 001-41929 |
Entity Registrant Name | ARRIVENT BIOPHARMA, INC. |
Entity Central Index Key | 0001868279 |
Entity Tax Identification Number | 86-3336099 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 18 Campus Boulevard |
Entity Address, Address Line Two | Suite 100 |
Entity Address, City or Town | Newtown Square |
Entity Address, State or Province | PA |
Entity Address, Postal Zip Code | 19073 |
City Area Code | 628 |
Local Phone Number | 277-4836 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.0001 par value per share |
Trading Symbol | AVBP |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |